After seeing their cities flooded and homes destroyed in Hurricane Harvey, Texas teachers and students spent the rest of the academic year struggling to get back to baseline, working through the negative academic and mental health effects of one of the worst natural disasters in the state's history. How are teachers and students focusing on classroom demands while continuing to pick up the pieces of their lives?

Join The Texas Tribune in person or on our livestream for a conversation about the impact Hurricane Harvey had on public education in Houston and across Texas moderated by the Tribune's public education reporter Aliyya Swaby.

A Right2Justice conversation on transforming our juvenile justice system. This is a system that for far too long has criminalized  and dehumanized young people of color, instead of providing them with the support and resources they need to get back into public life and enter the workforce. At this event, we'll be having discussions on what a reformed juvenile justice system looks like.

People of Faith in the 21st Century: What is Our Role?
Presenter: TBD

Iftar and Kosher dinner served.

Free and open to the public

RSVP required 

Prescription drug expenditures are projected to reach $360.2 billion in 2018. Per capita spending on these drugs rose 5 percent in 2015 and 3.5 percent in 2016. The public is outraged by stories of Martin Shkreli raising the price of Daraprim by 5,000 percent, and Mylan raising the price of a pair of EpiPens by 400 percent. Meanwhile, the cost of treatment with the most novel anticancer drugs has risen by 400 percent over the past 10 years, and the cost of treatment with new drugs that can cure Hepatitis C is tens of thousands of dollars. Will the prices of prescription drugs continue to rise at extraordinary rates? Are a handful of blockbuster drugs to blame, or will all patients be forced to pay rapidly rising prices? At this event, Vivian Ho, director of the Baker Institute Center for Health and Biosciences, will explore these questions and describe the policy options to control drug price increases being recommended by policymakers, researchers and clinicians.